Although popular models suggest that β-catenin phosphorylation/ubiquitination should be inhibited by APC mutations, it has been documented that different APC mutation types have different degradation efficiencies for β-catenin, which contributes to different levels of tumor progression64–66. Here, APC is linked to neoplasm.